Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.12M | -18.92M | -19.25M | -19.88M | -20.78M |
| Total Depreciation and Amortization | 207.30K | 338.00K | 288.10K | 238.90K | 190.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 600.00K | 618.40K | 243.80K | 351.70K | 549.40K |
| Change in Net Operating Assets | 635.30K | 1.11M | 850.00K | 166.50K | 2.23M |
| Cash from Operations | -15.68M | -16.86M | -17.87M | -19.12M | -17.81M |
| Capital Expenditure | -1.80K | -4.90K | -7.30K | -11.60K | -12.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.06M | 16.21M | 10.97M | 7.18M | 3.38M |
| Cash from Investing | 11.06M | 16.21M | 10.96M | 7.16M | 3.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.64M | 971.80K | 12.00K | 12.00K | 66.70K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -139.70K | -- | -- | -- | -- |
| Cash from Financing | 1.50M | 971.80K | 12.00K | 12.00K | 66.70K |
| Foreign Exchange rate Adjustments | 33.40K | -36.80K | -20.30K | -36.90K | -49.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.09M | 286.70K | -6.92M | -11.98M | -14.43M |